Your browser is no longer supported. Please, upgrade your browser.
SCYX SCYNEXIS, Inc. daily Stock Chart
Index- P/E- EPS (ttm)-3.48 Insider Own5.97% Shs Outstand10.63M Perf Week-8.96%
Market Cap68.45M Forward P/E- EPS next Y-3.17 Insider Trans0.00% Shs Float10.29M Perf Month38.70%
Income-26.90M PEG- EPS next Q-0.98 Inst Own44.60% Short Float1.98% Perf Quarter19.23%
Sales0.00M P/S- EPS this Y-237.10% Inst Trans-1.03% Short Ratio2.21 Perf Half Y-28.17%
Book/sh0.90 P/B6.89 EPS next Y-49.50% ROA-59.60% Target Price- Perf Year-35.70%
Cash/sh2.67 P/C2.32 EPS next 5Y- ROE-305.70% 52W Range4.20 - 12.10 Perf YTD-31.87%
Dividend- P/FCF- EPS past 5Y5.60% ROI-204.80% 52W High-48.76% Beta2.17
Dividend %- Quick Ratio3.90 Sales past 5Y-37.40% Gross Margin- 52W Low47.59% ATR0.51
Employees27 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)56.13 Volatility9.22% 9.04%
OptionableYes Debt/Eq1.39 EPS Q/Q104.80% Profit Margin- Rel Volume0.76 Prev Close6.70
ShortableYes LT Debt/Eq1.39 Earnings- Payout- Avg Volume92.11K Price6.20
Recom1.80 SMA206.13% SMA5018.76% SMA200-11.42% Volume69,346 Change-7.46%
Jul-11-18Upgrade Needham Hold → Buy $5
Jun-27-18Initiated Maxim Group Buy $6
Oct-24-17Initiated Guggenheim Buy $6
Jul-10-17Initiated ROTH Capital Buy $8.50
May-09-17Downgrade Needham Buy → Hold
Mar-03-17Reiterated RBC Capital Mkts Outperform $15 → $11
Oct-20-16Initiated H.C. Wainwright Buy $14
Oct-07-16Upgrade WBB Securities Buy → Strong Buy $8
Oct-03-16Resumed Brean Capital Buy
Aug-17-16Initiated Guggenheim Buy $15
Aug-09-16Upgrade WBB Securities Speculative Buy → Buy $8
Aug-09-16Reiterated Needham Buy $16 → $10
Mar-28-16Initiated Brean Capital Buy $16
Dec-29-15Initiated WBB Securities Strong Buy $8
Dec-29-15Initiated WBB Securities Speculative Buy $8
Nov-16-15Reiterated RBC Capital Mkts Outperform $18 → $17
Jun-10-15Initiated Needham Buy $16
May-29-14Initiated RBC Capital Mkts Outperform $17
May-29-14Initiated Canaccord Genuity Buy $18
Nov-27-20 02:36PM  
Nov-24-20 09:35AM  
Nov-09-20 02:21PM  
Nov-06-20 08:45AM  
Oct-21-20 08:30AM  
Oct-14-20 08:30AM  
Oct-12-20 08:30AM  
Sep-10-20 08:38AM  
Aug-13-20 08:00AM  
Aug-10-20 08:20AM  
Jul-29-20 08:00AM  
Jul-22-20 08:51AM  
Jul-16-20 09:00AM  
Jul-09-20 08:00AM  
Jul-06-20 05:19PM  
Jun-08-20 09:51AM  
Jun-04-20 06:17PM  
Jun-02-20 08:00AM  
Jun-01-20 09:56AM  
May-11-20 08:50AM  
May-06-20 08:00AM  
Apr-28-20 08:00AM  
Apr-27-20 02:40PM  
Apr-21-20 07:00AM  
Apr-13-20 08:55AM  
Apr-09-20 08:53AM  
Mar-26-20 08:00AM  
Mar-13-20 12:31PM  
Mar-11-20 08:18AM  
Mar-05-20 08:00AM  
Feb-13-20 08:08AM  
Jan-09-20 07:05AM  
Jan-08-20 07:30AM  
Dec-20-19 05:33PM  
Dec-16-19 08:30AM  
Dec-12-19 12:46PM  
Dec-10-19 07:56AM  
Dec-09-19 04:01PM  
Nov-19-19 12:49PM  
Nov-14-19 08:30AM  
Nov-12-19 09:45AM  
Nov-07-19 08:00AM  
Nov-05-19 10:32AM  
Oct-31-19 08:30AM  
Oct-24-19 08:30AM  
Oct-10-19 08:30AM  
Oct-02-19 08:30AM  
Oct-01-19 12:27PM  
Sep-18-19 08:30AM  
Sep-04-19 07:00AM  
Aug-21-19 10:40AM  
Aug-14-19 02:38PM  
Aug-07-19 06:55PM  
Aug-01-19 10:33AM  
Jul-31-19 08:00AM  
Jul-24-19 08:00AM  
Jul-01-19 09:13AM  
Jun-25-19 08:30AM  
Jun-20-19 11:13AM  
Jun-19-19 01:18PM  
Jun-14-19 08:30AM  
Jun-07-19 09:27AM  
Jun-05-19 08:30AM  
May-30-19 08:30AM  
May-08-19 07:35PM  
May-07-19 10:30AM  
May-06-19 08:30AM  
May-01-19 08:30AM  
Apr-15-19 08:30AM  
Apr-13-19 09:38AM  
Apr-12-19 10:08AM  
Apr-08-19 08:15AM  
Apr-03-19 08:30AM  
Apr-01-19 08:00AM  
Mar-14-19 04:39PM  
Mar-07-19 09:34AM  
Feb-28-19 09:50AM  
Jan-31-19 09:20AM  
Jan-30-19 04:05PM  
Jan-22-19 08:45AM  
Jan-21-19 11:24AM  
Jan-17-19 10:00AM  
Jan-04-19 07:59AM  
Jan-03-19 04:05PM  
Nov-23-18 08:00AM  
Nov-20-18 08:00AM  
Nov-13-18 10:25AM  
Oct-23-18 09:00AM  
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Taglietti MarcoChief Executive OfficerDec 12Buy0.90166,667150,000693,682Dec 16 03:10 PM